Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 142 publications
Advances in immunotherapies in ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: June 03, 2026
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.
Journal: Science (New York, N.Y.)
Published: February 26, 2026
Rethinking ovarian cancer III: the past decade and future directions.
Journal: Nature reviews. Cancer
Published: February 23, 2026
Radiation Quality and Workflow in NRG GY017: Anti-PD-L1 (Atezolizumab) as an Immune Primer or Concurrently With Radiation Therapy for Node-Positive Locally Advanced Cervical Cancer.
Journal: International journal of radiation oncology, biology, physics
Published: January 12, 2026
Radiation Quality and Workflow in NRG GY017: Anti PD-L1 (Atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer.
Journal: International journal of radiation oncology, biology, physics
Published: January 12, 2026
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 07, 2026
CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).
Journal: Cancer treatment and research communications
Published: September 30, 2025
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.
Journal: Cell
Published: August 19, 2025
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.
Journal: Gynecologic oncology
Published: August 01, 2025
Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer.
Journal: Nature immunology
Published: June 26, 2025
Early-stage uterine papillary serous carcinoma: Clinical outcomes in patients treated with adjuvant chemotherapy and vaginal brachytherapy.
Journal: Gynecologic oncology
Published: May 07, 2025
A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era.
Journal: Journal of the National Cancer Institute
Published: January 09, 2025
Last Updated: 09/26/2026